Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › DTG

DTG

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of DTG

8 trials tracked of DTG: 4 in phase 3 or 4 and 4 with published results. The most-cited published study has 395 citations.

8Trials tracked
4Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 4 Phase 2 2 Phase 1 2
  1. Phase 3 Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Completed · 395 cited
  2. Phase 3 Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment Completed · 198 cited
  3. Phase 3 Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed Completed · 112 cited
  4. Phase 3 Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults Completed · 59 cited
  5. Phase 2 Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults Completed
  6. Phase 2 Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study Completed
Show 2 more trials
  1. Phase 1 A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants Completed
  2. Phase 1 Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG) Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bictegravir/emtricitabine/tenofovir alafenamide shows favorable lipid and renal changes versus other regimens in treatment-experienced HIV-1 patients
Infectious Disease Sys. Review
Bictegravir/emtricitabine/tenofovir alafenamide shows favorable lipid and renal changes versus other regimens in treatment-experienced HIV-1 patients New review shows a specific HIV drug combo may improve cholesterol and kidney health
This systematic literature review and network meta-analysis evaluates bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) against othe…
A large review found that a specific HIV drug combination improved cholesterol and kidney function compared to other common treatments for e…
Jun 4, 2026